Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA panel will review drug-associated suicidality study

Executive Summary

FDA will discuss the results of its analysis of suicidality from placebo-controlled trials of 11 drugs at a joint advisory committee meeting, which could lead to broad class labeling changes. Members of the Peripheral and Central Nervous System Drugs, Psychopharmacological Drugs, Pediatric, and Drug Safety and Risk Management Advisory Committees will meet July 10 to consider the analysis and determine whether any additional actions are necessary. Findings of increased risk of suicidality in patients taking antiepileptic drugs were noted in a MedWatch alert issued in January (1"The Pink Sheet," Feb. 4, 2008, p. 3)

You may also be interested in...

Antiepileptics Show Risk Of Suicidality, May Cause Labeling Convulsions

FDA findings of an increased risk of suicidality in patients given antiepileptic drugs will likely lead to broad class labeling changes, according to a MedWatch alert issued Jan. 31

Lilly’s ‘High Quality’ Donanemab Data Supports Unrestricted Medicare Coverage, Firm Says

As FDA decision on Alzheimer’s product approaches, new paper outlines Lilly’s arguments for unfettered Medicare coverage for donanemab once it is approved.

Oncopeptides’ Pepaxto Withdrawal Speeds Through In 7 Months Under Expedited Procedures

Of three accelerated approval drugs that have been ordered withdrawn to date, Pepaxto marks the shortest interval between the FDA drugs center's withdrawal proposal and the agency’s final order, suggesting that FDORA’s expedited withdrawal procedures helped move things along more quickly.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts